Given the fact that many of these checkpoint proteins are well-characterized cancer targets and many of their inhibitors are currently being developed at the different phases of clinical trials,49, 50 therefore, the finding that silencing NFBD1 impairs G2/M checkpoint and DNA damage repair makes NFBD1 a more appealing anticancer target. The gene discussed is MDC1; the disease is cancer.